Enoblituzumab

Drug identity checked against registry records

Also recorded as MGA271

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825MacroGenicsPhase 2Terminated2022-07-29Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.